2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Factor Xa

Factor Xa

Fxa

Factor Xa

Related Products

PDF 0.5 MB

Factor Xa, a trypsin-like serine protease, is situated at the critical juncture between the intrinsic and extrinsic pathways, catalyzing the conversion of prothrombin to thrombin, and hence plays a pivotal role in the final common pathway of the cascade and has become an important target in the discovery and development of new anticoagulants. Factor Xa is a key protease of the coagulation pathway whose activity is known to be in part modulated by binding to factor Va and sodium ions.

Blood coagulation involves a complex cascade of enzymatic reactions, ultimately generating fibrin, the basis of all blood clots. This cascade is comprised of two arms, the intrinsic and extrinsic pathways which converge at factor Xa to form the common pathway. Factor Xa activates prothrombin to thrombin, which in turn catalyzes the conversion of fibrinogen to fibrin.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99794
    Osocimab
    		Inhibitor 98.00%
    Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects.
    Osocimab
  • HY-18660
    Ciraparantag
    		Inhibitor 98.0%
    Ciraparantag (PER977) is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban.
    Ciraparantag
  • HY-153829
    CH3OCO-D-CHA-Gly-Arg-pNA acetate
    		98.88%
    CH3OCO-D-CHA-Gly-Arg-pNA acetate is a chromogenic substrate for factor Xa.
    CH3OCO-D-CHA-Gly-Arg-pNA acetate
  • HY-70035
    Otamixaban
    		Inhibitor 98.25%
    Otamixaban(FXV673) is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa.
    Otamixaban
  • HY-50903S
    Rivaroxaban-d4
    		Inhibitor 98.73%
    Rivaroxaban-d4 is a deuterium labeled Rivaroxaban. Rivaroxaban is a highly potent，selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).
    Rivaroxaban-d<sub>4</sub>
  • HY-P2008
    Boc-Ile-Glu-Gly-Arg-AMC
    		99.50%
    Boc-Ile-Glu-Gly-Arg-AMC (IEGR-AMC) is an activated factor X (FXa) specific fluorogenic peptide substrate used for Factor VIII determination.
    Boc-Ile-Glu-Gly-Arg-AMC
  • HY-P99283
    Concizumab
    Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia.
    Concizumab
  • HY-153480A
    ARC19499 sodium
    ARC19499 sodium is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 sodium blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 sodium corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.
    ARC19499 sodium
  • HY-76971
    Dechloro Rivaroxaban
    		Inhibitor 99.68%
    Dechloro Rivaroxaban is a highly selective, orally active inhibitor of Factor Xa. Dechloro Rivaroxaban inhibits human free FXa with a Ki of 0.4 nM. Dechloro Rivaroxaban inhibits prothrombinase activity and fibrin-associated FXa activity with IC50s of 2.1 nM and 92 nM, respectively.
    Dechloro Rivaroxaban
  • HY-117290
    BMS-962212
    		Inhibitor 99.33%
    BMS-962212 is a direct, reversible, selective factor XIa (FXIa) inhibitor . BMS-962212 is well tolerated, with fast onset of pharmacodynamic (PD) responses and rapid elimination. BMS-962212 increases exposure dependently in activated partial thromboplastin time, and decreases exposure dependently in FXI clotting activity.
    BMS-962212
  • HY-132587A
    Fitusiran sodium
    		98.17%
    Fitusiran sodium, an small interfering RNA, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran sodium increases thrombin generation and has the potential for the research of the hemophilia.
    Fitusiran sodium
  • HY-163348
    FXIIa-IN-4
    		Inhibitor 98.87%
    FXIIa-IN-4 (compound 22) is a potent, selective human FXIIa inhibitor with the IC50 of 0.032 μM, 0.30 μM, ＞50 μM for FXIIa, thrombin and FXIa, respectively. FXIIa-IN-4 can be used for study of anticoagulant.
    FXIIa-IN-4
  • HY-10264S
    Edoxaban-d6
    		Inhibitor 99.6%
    Edoxaban-d6 is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment.
    Edoxaban-d<sub>6</sub>
  • HY-76948
    5-R-Rivaroxaban
    		Inhibitor 99.97%
    5-R-Rivaroxaban is (R)-enantiomer of Rivaroxaban. Rivaroxaban (BAY 59-7939) is a highly potent and selective, direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).
    5-R-Rivaroxaban
  • HY-N2082
    Isorhamnetin 3-O-galactoside
    		Inhibitor 99.64%
    Isorhamnetin 3-O-galactoside (Cacticin) is a flavonoid glycoside that can be isolated from Oenanthe javanica, with antithrombotic and profibrinolytic activities. Isorhamnetin 3-O-galactoside inhibits the activities of thrombin and factor Xa (FXa) and reduces thrombin-catalyzed fibrin polymerization maximum rate. Isorhamnetin 3-O-galactoside suppresses TNF-α-induced PAI-1 secretion, decreases the PAI-1/tissue-type plasminogen activator (t-PA) ratio, and inhibits FXa production and FVa/FXa-mediated thrombin generation. Isorhamnetin 3-O-galactoside exerts protective effects against Carbon tetrachloride (CCl4) (HY-Y0298)-induced hepatic injury in mice. Isorhamnetin 3-O-galactoside can be used for the study of liver injury-related diseases and thrombotic vascular diseases.
    Isorhamnetin 3-O-galactoside
  • HY-107966A
    Heparin calcium (MW 3600-5000)
    		Inhibitor
    Heparin (Nadroparin) calcium (MW 3600-5000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin.
    Heparin calcium (MW 3600-5000)
  • HY-76835
    5-Chlorothiophene-2-carboxylic acid
    		99.86%
    5-Chlorothiophene-2-carboxylic acid is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    5-Chlorothiophene-2-carboxylic acid
  • HY-162558
    NCGC00351170
    		Inhibitor 99.05%
    NCGC00351170 is an antiplatelet agent that disrupts the calcium and integrin-binding protein 1 (CIB1)-αIIbβ3 interaction. NCGC00351170 inhibits thrombin-induced human platelet aggregation.
    NCGC00351170
  • HY-14853
    Darexaban
    		Inhibitor 98.05%
    Darexaban (YM150) is a potent, selective and orally active factor Xa (FXa) inhibitor with an IC50 of 54.6 nM. Darexaban shows high selectivity against other related serine proteases, such as trypsin, thrombin, and kallikrein. Darexaban has anticoagulant and antithrombotic effects.
    Darexaban
  • HY-50667S1
    Apixaban-d3
    		Inhibitor
    Apixaban-d3 (BMS-562247-01-d3) is the deuterium labeled Apixaban (HY-50667). Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively. Apixaban is in development for the prevention and treatment of various thromboembolic diseases.
    Apixaban-d<sub>3</sub>
Cat. No. Product Name / Synonyms Application Reactivity